A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Clinical trial NCT06244771 · RECRUITING

Trial details

NCT number: NCT06244771
Sponsor: Frontier Medicines Corporation
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors With KRAS G12C Mutations Solid Tumor, Adult Unresectable Solid Tumor Metastatic Solid Tumor Non Small Cell Lung Cancer Colorectal Cancer KRAS G12C Pancreatic Cancer

Start date: 2024-02-12
Primary completion: 2027-10-01
Enrollment: 403

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.